125.19 USD
▲-1.14+0.33%
2026-08-03
市值
$10.79B
市盈率
—
EPS
-5.22
股息率
—
52 周区间
67.09 – 148.83
成交量
634.79K
Beta
-0.21
目标价
165.91
52W 低 67.0952W 高 148.83
价格走势
公司简介
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.